206 related articles for article (PubMed ID: 20529786)
1. Myelodysplastic syndromes: clinical practice guidelines in oncology.
Greenberg PL; Attar E; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; Frankfurt O; Gaensler K; Garcia-Manero G; Gore SD; Head D; Komrokji R; Maness LJ; Millenson M; O'Donnell MR; Shami PJ; Stein BL; Stone RM; Thompson JE; Westervelt P; Wheeler B; Shead DA; Naganuma M
J Natl Compr Canc Netw; 2013 Jul; 11(7):838-74. PubMed ID: 23847220
[TBL] [Abstract][Full Text] [Related]
2. The revolution of myelodysplastic syndromes.
Sekeres MA; Bejanyan N
Ther Adv Hematol; 2011 Feb; 2(1):33-43. PubMed ID: 23556074
[TBL] [Abstract][Full Text] [Related]
3. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.
Greenberg PL; Attar E; Bennett JM; Bloomfield CD; De Castro CM; Deeg HJ; Foran JM; Gaensler K; Garcia-Manero G; Gore SD; Head D; Komrokji R; Maness LJ; Millenson M; Nimer SD; O'Donnell MR; Schroeder MA; Shami PJ; Stone RM; Thompson JE; Westervelt P;
J Natl Compr Canc Netw; 2011 Jan; 9(1):30-56. PubMed ID: 21233243
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of higher-risk myelodysplastic syndromes: future prospects.
Gener-Ricos G; Rodriguez-Sevilla JJ; Urrutia S; Bataller A; Bazinet A; Garcia-Manero G
Leuk Lymphoma; 2024 May; ():1-12. PubMed ID: 38712556
[TBL] [Abstract][Full Text] [Related]
5. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.
Garcia JS; Jain N; Godley LA
Onco Targets Ther; 2010 Jun; 3():1-13. PubMed ID: 20616953
[TBL] [Abstract][Full Text] [Related]
6. Clinical decision-making and treatment of myelodysplastic syndromes.
Hellström-Lindberg ES; Kröger N
Blood; 2023 Dec; 142(26):2268-2281. PubMed ID: 37874917
[TBL] [Abstract][Full Text] [Related]
7. The role of azacitidine in the management of myelodysplastic syndromes (MDS).
Götze K; Müller-Thomas C; Peschel C
Cancer Manag Res; 2009 Oct; 1():119-30. PubMed ID: 21188130
[TBL] [Abstract][Full Text] [Related]
8. Vaccines: a promising therapy for myelodysplastic syndrome.
Gera K; Chauhan A; Castillo P; Rahman M; Mathavan A; Mathavan A; Oganda-Rivas E; Elliott L; Wingard JR; Sayour EJ
J Hematol Oncol; 2024 Jan; 17(1):4. PubMed ID: 38191498
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
Kurtin S; Knop CS; Milliron T
J Adv Pract Oncol; 2012 Nov; 3(6):406-10. PubMed ID: 25031973
[TBL] [Abstract][Full Text] [Related]
10. Novel agents for the management of myelodysplastic syndromes.
Meletis J; Viniou N; Terpos E
Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
[TBL] [Abstract][Full Text] [Related]
11. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
13. An update on the treatment of myelodysplastic syndromes.
Kurtin SE; Demakos EP
Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
[TBL] [Abstract][Full Text] [Related]
14. Treatment of myelodysplastic syndromes in elderly patients.
Sanchez JF
Adv Ther; 2011 Mar; 28 Suppl 2():1-9. PubMed ID: 21431504
[TBL] [Abstract][Full Text] [Related]
15. Incorporating novel agents in the treatment of myelodysplastic syndromes.
Anargyrou K; Vassilakopoulos TP; Angelopoulou MK; Terpos E
Leuk Res; 2010 Jan; 34(1):6-17. PubMed ID: 19656566
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
